Plain-English translation of NCT07379268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This trial is testing a medication called vedicitumumab, which is designed to attack bladder cancer cells that have a specific protein called HER2 on their surface. What makes this study unique is that instead of deciding who gets the treatment based only on a tumor biopsy, researchers will grow a small sample of your tumor in the lab and test whether your cancer cells actually respond to the medication before you receive it.
Some patients with advanced bladder cancer benefit greatly from this type of treatment, while others do not — and doctors cannot always predict who will respond just by looking at tumor samples under a microscope. This trial tests whether growing your tumor in the lab and testing it against the medication first can help doctors choose which patients are most likely to benefit.
You likely qualify if…
You likely don't qualify if…
If you enroll, a small tumor sample will be collected from you and grown in the laboratory to test how it responds to the medication. Based on these results, you will either receive the new treatment (if your tumor shows sensitivity) or be followed as part of a comparison group. You will have regular clinic visits to monitor how the treatment works and to check for any side effects, with follow-up care continuing after treatment ends.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China